Project Grant R44AG054386

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $560,000 to Baylor College of Medicine to perform preclinical testing and development of a novel "triple gene therapy" approach for treating ischemic heart failure. The proposed therapy aims to regenerate damaged heart muscle by inducing cardiomyocyte proliferation, direct cardiac reprogramming of fibroblasts, and enhancing...

This $693,261 federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to Baylor College of Medicine aims to investigate the Hippo-YAP signaling pathway and its role in promoting cardiac regenerative repair following myocardial infarction. The central hypothesis is that gene therapy strategies to knock down Hippo signaling in cardiac tissue can improve cardiac function in mouse models of ischemic heart failure. Key objectives...

This Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI), under CFDA Program 93.837 Cardiovascular Diseases Research, is funding research to develop an ultrasound-based approach for delivering microRNA-92a inhibitor (antimir-92a) to the heart to prevent adverse cardiac remodeling following acute myocardial infarction. The $791,485 award will support experiments in rat and porcine models to define the optimal antimir-92a dose and test the efficacy and safety of...

This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $125,250 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct a 2-year research study on the role of the cytokine FAM3D in heart failure. The principal investigator, Dr. James Rhee, will lead a team of scientists to investigate how FAM3D regulates cardiac fibroblasts and the lymphatic system to limit inflammation and...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $1,488,899 to Young Therapeutics LLC to develop and validate two proprietary protein kinase inhibitor compounds, YT-002 and YT-004. The research aims to advance these compounds through preclinical studies, including optimizing drug formulations, conducting detailed pharmacokinetic and pharmacodynamic assessments, and performing long-term...

The National Heart, Lung, and Blood Institute (NHLBI) awarded a $317,285 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Rithim Biologics Inc. to develop a novel gene therapy approach to prevent ventricular tachycardia (VT) following a myocardial infarction. The project aims to finalize the development of an epicardial gene painting catheter, verify targeted ventricular gene expression, and evaluate the safety and efficacy of the gene therapy in a porcine...

This Project Grant award of $786,188, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop a novel gene therapy platform to prevent the failure of prosthetic bypass grafts used to treat arterial blockages in the lower extremities. The research, conducted by Beth Israel Deaconess Medical Center, Inc. (BIDMC), focuses on optimizing a biodegradable hydrogel system that can deliver small interfering RNA...

This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $542,094 to advance the preclinical development of a liposomal formulation of the antibiotic azithromycin (L-AZM) for treating cardiac inflammation associated with conditions like myocardial infarction (MI). The overall goal is to identify an L-AZM treatment regimen that can reduce pathological inflammation and improve outcomes for patients. The R61 phase will...

This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will fund a $195,480 research project led by Dr. Cunningham at Brigham and Women's Hospital. The project aims to investigate the effects of neprilysin inhibition on myocardial interstitial fibrosis, a key cause of heart failure with preserved ejection fraction (HFPEF), which affects 2.5 million Americans. The study will use cardiac MRI,...

This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program provides $385,381 to Trustees of Tufts College, a private research university, to develop and evaluate injectable, elastic silk-cardiac extracellular matrix (CECM) composite hydrogels for stabilizing the ventricular wall and promoting cardiac tissue repair following myocardial infarction. The goal is to create biomaterials that can dynamically mimic...